Application of diffusion-weighted imaging combined with apparent diffusion coefficient in differential diagnosis between central neurocytoma and ependymoma.

PURPOSE: Differential diagnosis between central neurocytoma and ependymoma is very important for making preoperative scheme. We explored the application of diffusion-weighted imaging (DWI) combined with apparent diffusion coefficient (ADC) in differential diagnosis between both. METHODS: The data of preoperative MR plain and contrast-enhanced scan, DWI and ADC values of neoplastic solid parts from 18 cases with central neurocytoma and 19 cases with lateral ventricular ependymoma, were retrospectively analyzed. Mann-Whitney test was used for the comparison of ADC values between central neurocytoma and ependymoma. The application of ADC values in the differential diagnosis between central neurocytoma and ependymoma was evaluated by ROC curve. RESULTS: The lesions showed hyperintensity-dominant mixed signal intensity on DWI and mean ADC was (0.65 ± 0.13) × 10-3 mm2/s in the 18 cases with central neurocytoma. In the 19 cases with ependymoma, 13 had hyperintensity-dominant mixed signal intensity on DWI and 6 had hypointensity-dominant mixed signal intensity on DWI, and mean ADC was (1.20 ± 0.23) × 10-3 mm2/s. The mean ADC value was significantly higher in the 19 cases with ependymoma than in the 18 cases with central neurocytoma (P < 0.001). The ADC of 0.87 × 10-3 mm2/s might be used as a threshold for differential diagnosis between central neurocytoma and ependymoma with an area under ROC curve of 0.98 ± 0.02 and a 95% confidence interval of 0.95-1.00. Its sensitivity, specificity, and accuracy were 90%, 100%, and 90%, respectively. CONCLUSION: There is a certain overlap in MRI imaging features between central neurocytoma and ependymoma. DWI combined with ADC value can improve peoperative diagnostic accuracy.

Variations and effects of bladder and rectal volume following uniform preparation procedure in cervical cancer: Five fractions of 6 Gy.

Purpose: To analyze the effects of different bladder and rectal volumes on the dose of organ at risks (OARs) and primary tumors following uniform preparation procedure. Material and methods: In this retrospective study, a total of 60 patients with cervical cancer treated with external beam radiation therapy (EBRT) combined with chemotherapy and brachytherapy (BT) during 2019-2022 were included (300 insertions). Then, tandem-ovoid applicators were placed and computed tomography (CT) scanning was performed after each insertion. Delineation of OARs and clinical target volumes (CTVs) were done according to GEC-ESTRO group recommendations. Finally, doses of high-risk clinical target volume (HR-CTV) and OARs were obtained from dose volume histogram (DVH) automatically generated by BT treatment planning system. Results: Following a uniform preparation procedure, the median bladder volume of 68.36 cc (range, 29.9-235.68 cc) was in optimal agreement with the recommended bladder volume of ≤ 70 ml, which avoided more manipulation and possible risk of adverse events during general anesthesia. As the bladder filling volume increased, there was no corresponding increase in rectal, HR-CTV, and small bowel volumes, while the sigmoid colon volume decreased. The median rectal volume was 54.95 cc (range, 24.92-168.1 cc), and as the rectal volume increased, HR-CTV, sigmoid colon, and rectum volumes increased, and conversely, small bowel volume decreased. HR-CTV changes with volume affected the rectum, bladder, and HR-CTV, but not the sigmoid colon and small intestine. Conclusions: Following a uniform preparation procedure, the bladder and rectum can also be controlled to an optimal volume (B ≤ 70 cc, R ≈ 40 cc), which is related to the dose of the bladder, rectum, and sigmoid colon.

Using Hyperbaric Oxygen to Improve the Radiosensitivity of Human U251 Glioma Cells.

The aim of this study was to explore the use of hyperbaric oxygen to enhance the radiosensitivity of human glioma cells. Sub-cultured U251 human glioma cells were randomly divided into four groups: an untreated control group, cells treated with hyperbaric oxygen (HBO) only, cells treated with X-ray irradiation (X-ray) only, and cells treated with both HBO and X-ray. Cell morphology, cell proliferation activity, cell cycle distribution, and apoptosis were observed in these groups to evaluate the role of HBO in improving the radiosensitivity of glioma cells. With the increase in X-ray doses (0 Gy, 2 Gy, 4 Gy, 6 Gy, 8 Gy), the survival fraction (SF) of glioma cells gradually decreased. Significantly lower SF was observed for the cells treated with the HBO and X-ray together than in the X-ray group for each dose (all P < 0.05). The proliferation inhibition was significantly higher in the HBO combined with X-ray group than in the X-ray group for each dose (all P < 0.05) for the U251 cell line. The percentage of G2/M phase cells was significantly higher in the HBO combined with X-ray (2 Gy) group (26.70% ± 2.46%) and the HBO group (22.36% ± 0.91%) than in the control group (11.56% ± 2.01%) and X-ray (2 Gy) group (10.35% ± 2.69%) (all P < 0.05). U251 cell apoptosis was significantly higher in the HBO combined with X-ray (2 Gy) group than in the HBO group, the X-ray (2 Gy) group, and the control group (all P < 0.05). We conclude that HBO can enhance the proliferation inhibition and apoptosis of glioma U251 cells by blocking glioma cells in the G2/M phase and improve the radiosensitivity of U251 glioma cells.